Technical Analysis for BWAY - Brainsway Ltd.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Flat |
Date | Alert Name | Type | % Chg |
---|---|---|---|
20 DMA Resistance | Bearish | 0.00% | |
New Uptrend | Bullish | 0.00% | |
Calm After Storm | Range Contraction | 0.00% | |
Multiple of Ten Bearish | Other | 0.00% | |
Gapped Up | Strength | 0.00% | |
Up 3 Days in a Row | Strength | 0.00% | |
1,2,3 Retracement Bearish | Bearish Swing Setup | 1.65% | |
50 DMA Support | Bullish | 1.65% | |
Calm After Storm | Range Contraction | 1.65% | |
Crossed Above 50 DMA | Bullish | 4.02% |
Alert | Time |
---|---|
Up 1 ATR | about 18 hours ago |
Up 5% | about 19 hours ago |
60 Minute Opening Range Breakout | about 19 hours ago |
10 DMA Support | about 21 hours ago |
20 DMA Resistance | about 22 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/12/2024
Brainsway is a commercial stage medical device company focused on the development and sale of non-invasive neuromodulation products using the Company’s proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD), for which Brainsway received marketing authorization from the U.S. Food and Drug Administration (FDA) in 2013 (for MDD) and in August 2018 (for OCD). Brainsway is currently conducting clinical trials of Deep TMS in other psychiatric, neurological and addiction disorders, including smoking cessation and post-traumatic stress disorder, and is planning trials for opioid addiction, fatigue in multiple sclerosis (MS) and post-stroke rehabilitation.
Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Neuroscience FDA Mental Health Opioids Multiple Sclerosis Psychiatry Stroke Major Depressive Disorder Neuromodulation Neurophysiology Depressive Disorder Neurotechnology Smoking Post Traumatic Stress Disorder Neuropsychology Smoking Cessation Treatment Of Major Depressive Disorder Obsessive Compulsive Disorder Addiction Neuromodulation Products Treatment Of Depression Non Invasive Neuromodulation Products
Classification
Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Neuroscience FDA Mental Health Opioids Multiple Sclerosis Psychiatry Stroke Major Depressive Disorder Neuromodulation Neurophysiology Depressive Disorder Neurotechnology Smoking Post Traumatic Stress Disorder Neuropsychology Smoking Cessation Treatment Of Major Depressive Disorder Obsessive Compulsive Disorder Addiction Neuromodulation Products Treatment Of Depression Non Invasive Neuromodulation Products
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 10.98 |
52 Week Low | 4.61 |
Average Volume | 99,835 |
200-Day Moving Average | 7.05 |
50-Day Moving Average | 9.40 |
20-Day Moving Average | 9.96 |
10-Day Moving Average | 9.85 |
Average True Range | 0.59 |
RSI (14) | 51.46 |
ADX | 33.61 |
+DI | 20.94 |
-DI | 18.48 |
Chandelier Exit (Long, 3 ATRs) | 9.20 |
Chandelier Exit (Short, 3 ATRs) | 10.44 |
Upper Bollinger Bands | 10.94 |
Lower Bollinger Band | 8.98 |
Percent B (%b) | 0.43 |
BandWidth | 19.73 |
MACD Line | 0.04 |
MACD Signal Line | 0.16 |
MACD Histogram | -0.1198 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 11.02 | ||||
Resistance 3 (R3) | 11.03 | 10.65 | 10.82 | ||
Resistance 2 (R2) | 10.65 | 10.35 | 10.64 | 10.75 | |
Resistance 1 (R1) | 10.24 | 10.16 | 10.05 | 10.23 | 10.69 |
Pivot Point | 9.86 | 9.86 | 9.77 | 9.85 | 9.86 |
Support 1 (S1) | 9.45 | 9.56 | 9.26 | 9.44 | 8.97 |
Support 2 (S2) | 9.07 | 9.37 | 9.06 | 8.91 | |
Support 3 (S3) | 8.66 | 9.07 | 8.84 | ||
Support 4 (S4) | 8.65 |